ArticleDose-response : a publication of International Hormesis Society
Phenotypic Age Acceleration and Risk of All-Cause and Cardiovascular Mortality in US Adults With Asthma: A Retrospective Cohort Study.
Article in Dose-response : a publication of International Hormesis Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Phenotypic age acceleration (PhenoAgeAccel) reflects biological aging, with higher values indicating faster aging. While linked to adverse outcomes in the general population, its relation to mortality in asthma remains unclear. Methods: We analyzed 3817 adults with physician-diagnosed asthma from NHANES (1999-2010, 2015-2018) with mortality follow-up through 2019. PhenoAgeAccel was calculated from clinical biomarkers, and associations with all-cause and cardiovascular mortality were assessed using weighted Cox models, restricted cubic splines, and subgroup/sensitivity analyses. Results: During a median follow-up of 13.2 years, higher PhenoAgeAccel was independently associated with greater risks of all-cause mortality (HR = 1.03, 95% CI: 1.03-1.04) and cardiovascular mortality (HR = 1.02, 95% CI: 1.01-1.04). Compared with the lowest quartile, participants in the highest had a 3.42-fold higher all-cause and 2.72-fold higher cardiovascular mortality risk. Associations were nonlinear for all-cause but roughly linear for cardiovascular mortality, and consistent across subgroups and sensitivity tests. Conclusions: Higher PhenoAgeAccel was independently associated with increased risks of all-cause and cardiovascular mortality among adults with asthma, indicating that biological aging markers may serve as useful tools for risk assessment and individualized care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.